

Hyung I Kim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8179464/hyung-l-kim-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

5,847
citations

41
h-index

75
g-index

126
ext. papers

6,729
ext. citations

4
avg, IF

5.13
L-index

#	Paper	IF	Citations
119	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , 2022 , 82, 439	12.1	0
118	Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. <i>Oncology</i> , 2021 , 35, 119-125	1.8	2
117	Robot-Assisted Surgery for Upper Tract Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2021 , 48, 71-80	2.9	1
116	Patient- and tumor-level risk factors for MRI-invisible prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 794-801	6.2	1
115	Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100. <i>Prostate</i> , 2020 , 80, 424-431	4.2	1
114	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020 , 10, e82-e90	2.8	7
113	Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis. <i>European Urology Open Science</i> , 2020 , 20, 37-47 ⁹	9.9	11
112	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.. <i>JCO Precision Oncology</i> , 2020 , 4, 1228-1238	3.6	0
111	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 136-143	6.2	16
110	Association of Wearable Activity Monitors With Assessment of Daily Ambulation and Length of Stay Among Patients Undergoing Major Surgery. <i>JAMA Network Open</i> , 2019 , 2, e187673	10.4	49
109	Downregulation of CENPF Remodels Prostate Cancer Cells and Alters Cellular Metabolism. <i>Proteomics</i> , 2019 , 19, e1900038	4.8	12
108	Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 927-929	5.1	8
107	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	4
106	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 399-405	6.2	28
105	Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. <i>Journal of Urology</i> , 2018 , 199, 1488-1493	2.5	9
104	Online physician ratings fail to predict actual performance on measures of quality, value, and peer review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018 , 25, 401-407	8.6	37
103	Robotic-Assisted Ureteral Reimplantation 2018 , 159-166		

102	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018 , 4, 636-638	5.1	8
101	Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. <i>Cell Cycle</i> , 2018 , 17, 2802-2818	4.7	31
100	Genes involved in prostate cancer progression determine MRI visibility. <i>Theranostics</i> , 2018 , 8, 1752-1765	12.1	31
99	Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2018 , 32, 730-736	2.7	5
98	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. <i>Cancer</i> , 2017 , 123, 2850-2859	6.4	44
97	Use of cylindrical coordinates to localize prostate cancers on MRI and prostatectomy pathology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 673.e15-673.e20	2.8	0
96	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. <i>Scientific Reports</i> , 2017 , 7, 7342	4.9	23
95	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 395-406	5.1	40
94	3D high-resolution diffusion-weighted MRI at 3T: Preliminary application in prostate cancer patients undergoing active surveillance protocol for low-risk prostate cancer. <i>Magnetic Resonance in Medicine</i> , 2016 , 75, 616-26	4.4	15
93	Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients. <i>EBioMedicine</i> , 2016 , 7, 80-4	8.8	5
92	ProPublica's Surgeon Scorecard: The Argument for Incorporating Appropriateness of Case Selection Into Surgeon Performance Assessment. <i>Urology</i> , 2016 , 95, 2-4	1.6	3
91	Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 907-914	0.6	11
90	Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 112.e15-21	2.8	41
89	Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis. <i>World Journal of Urology</i> , 2015 , 33, 1807-14	4	4
88	Multiparametric MRI Improves Accuracy of Clinical Nomograms for Predicting Extracapsular Extension of Prostate Cancer. <i>Urology</i> , 2015 , 86, 332-7	1.6	88
87	Multiparametric magnetic resonance imaging localizes established extracapsular extension of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 109.e15-22	2.8	36
86	Learning curves for robot-assisted and laparoscopic partial nephrectomy. <i>Journal of Endourology</i> , 2015 , 29, 297-303	2.7	49
85	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015 , 2, 1814-20	8.8	11

84 Molecularly Targeted Staging Strategies in Renal Cell Carcinoma **2015**, 541-553

83 Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. *Cancer Research*, **2014**, 74, 2217-28 10.1 29

82 Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. *PLoS ONE*, **2014**, 9, e88967 3.7 36

81 Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition. *Oncotarget*, **2014**, 3, e29081 7.2 1

80 Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq. *BMC Genomics*, **2014**, 15, 1087 4.5 51

79 Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1/CAATPs signaling axis. *Oncotarget*, **2014**, 5, 10114-26 3.3 42

78 Evaluation of a high-throughput, microfluidics platform for performing TaqMan[®] qPCR using formalin-fixed paraffin-embedded tumors. *Bioanalysis*, **2013**, 5, 1623-33 2.1 6

77 Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. *Journal of Urology*, **2013**, 189, 702-710 2.5 65

76 Gender disparity in kidney cancer treatment: women are more likely to undergo radical excision of a localized renal mass. *Urology*, **2013**, 82, 1065-9 1.6 10

75 Large oncosomes mediate intercellular transfer of functional microRNA. *Cell Cycle*, **2013**, 12, 3526-36 4.7 157

74 A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. *PLoS ONE*, **2013**, 8, e54918 3.7 49

73 Initial experience with arterial spin-labeling MR imaging to assess histology of renal masses. *Quantitative Imaging in Medicine and Surgery*, **2013**, 3, 130-1 3.6 3

72 The potential role for neoadjuvant therapy in renal cell carcinoma. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 777-82 0.6 3

71 Perioperative and renal function outcomes of minimally invasive partial nephrectomy for T1b and T2a kidney tumors. *Journal of Endourology*, **2012**, 26, 244-8 2.7 13

70 PDEF in prostate cancer. *Prostate*, **2012**, 72, 592-6 4.2 15

69 Intermediate-term oncological efficacy of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell testicular cancer. *BJU International*, **2012**, 109, 281-5 5.6 7

68 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials **2012**, 271-282

67 Simplified laparoscopic partial nephrectomy using a single-layer closure and no bolsters for renal tumors. *Urology*, **2011**, 77, 344-9 1.6 2

66	Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?. <i>Urology</i> , 2011 , 78, 595-600	1.6	19
65	Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 161-76	6.7	165
64	Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>BJU International</i> , 2011 , 107, 642-6	5.6	77
63	RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. <i>BJU International</i> , 2011 , 108, 876-81	5.6	83
62	Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. <i>Journal of Proteome Research</i> , 2011 , 10, 1765-71	5.6	58
61	Pattern recognition scavenger receptor CD204 attenuates Toll-like receptor 4-induced NF-kappaB activation by directly inhibiting ubiquitination of tumor necrosis factor (TNF) receptor-associated factor 6. <i>Journal of Biological Chemistry</i> , 2011 , 286, 18795-806	5.4	66
60	Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. <i>Journal of Biomolecular Screening</i> , 2010 , 15, 80-5		12
59	Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2010 , 184, 87-91	2.5	97
58	Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. <i>Urology</i> , 2010 , 76, 610-3	1.6	82
57	Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. <i>Urology</i> , 2010 , 76, 1111-6	1.6	42
56	Covalent crosslinking of tumor antigens stimulates an antitumor immune response. <i>Vaccine</i> , 2010 , 28, 6613-20	4.1	4
55	Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 184, 859-64	2.5	97
54	A method for using life tables to estimate lifetime risk for prostate cancer death. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 148-54	7.3	11
53	The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2010 , 58, 197-202	10.2	176
52	Reply from authors re: Urs E. Studer, Laurence Collette. Robot-assisted cystectomy: does it meet expectations? <i>Eur Urol</i> 2010;58:203-4. <i>European Urology</i> , 2010 , 58, 204-6	10.2	
51	Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 1086-94	4	23
50	Apical margins after robot-assisted radical prostatectomy: does technique matter?. <i>Journal of Endourology</i> , 2009 , 23, 123-7	2.7	45
49	Does the presence of significant risk factors affect perioperative outcomes after robot-assisted radical cystectomy?. <i>BJU International</i> , 2009 , 104, 986-90	5.6	24

48	Optical imaging in oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 298-300	2.8	5
47	Robot-assisted ureterectomy and ureteral reconstruction for urothelial carcinoma. <i>Journal of Endourology</i> , 2009 , 23, 97-100	2.7	42
46	Estimation and prediction of renal function in patients with renal tumor. <i>Journal of Urology</i> , 2009 , 181, 2451-60; discussion 2460-1	2.5	28
45	Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. <i>Blood</i> , 2009 , 113, 5819-28	2.2	60
44	The learning curve for robot-assisted radical cystectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2009 , 13, 509-14	2.2	38
43	Impact of previous abdominal surgery on robot-assisted radical cystectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2009 , 13, 398-405	2.2	21
42	Molecular Markers for Predicting Prognosis of Renal Cell Carcinoma 2009 , 449-471		1
41	The lymph node yield during robot-assisted radical cystectomy. <i>BJU International</i> , 2008 , 102, 231-4; discussion 234	5.6	68
40	Impact of tumour volume on surgical and pathological outcomes after robot-assisted radical cystectomy. <i>BJU International</i> , 2008 , 102, 840-3	5.6	28
39	Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. <i>Urology</i> , 2008 , 71, 287-91	1.6	26
38	Median lobe in robot-assisted radical prostatectomy: evaluation and management. <i>Urology</i> , 2008 , 71, 810-3	1.6	33
37	Molecular markers for predicting prognosis of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 113-24	2.8	33
36	INTERNATIONAL ROBOT-ASSISTED CYSTECTOMY CONSORTIUM (IRCC): IMMEDIATE ONCOLOGIC RESULTS AFTER ONE HUNDRED AND SIXTY TWO CASES. <i>Journal of Urology</i> , 2008 , 179, 295-295	2.5	4
35	Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3867-77	6.1	20
34	Prognostic factors and selection for clinical studies of patients with kidney cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 235-62	7	60
33	Impact of body mass index on robot-assisted radical cystectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2008 , 12, 241-5	2.2	36
32	Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. <i>BioTechniques</i> , 2007 , 43, 639-40, 642-3, 647	2.5	23
31	Clinical presentation of epithelioid angiomyolipoma. <i>International Journal of Urology</i> , 2007 , 14, 21-5	2.3	51

30	Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1097-105	7.4	29
29	Rapid communication: robot-assisted anterior exenteration: technique and initial series. <i>Journal of Endourology</i> , 2007 , 21, 633-9	2.7	21
28	Robot-assisted radical cystectomy and pelvic lymph node dissection: initial experience at Roswell Park Cancer Institute. <i>Urology</i> , 2007 , 69, 469-74	1.6	149
27	Patient Selection and Perioperative Management 2007 , 47-53		2
26	Robot-assisted radical cystectomy versus open radical cystectomy: assessment of postoperative pain. <i>Canadian Journal of Urology</i> , 2007 , 14, 3753-6	0.8	39
25	Heat shock proteins HSP70 and GP96: structural insights. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 339-46	7.4	20
24	Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 227-31	3.3	2
23	Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2005 , 173, 1496-501	2.5	184
22	Heat shock proteins and scavenger receptors: role in adaptive immune responses. <i>Immunological Investigations</i> , 2005 , 34, 325-42	2.9	24
21	Staging of renal cell carcinoma: current concepts. <i>BJU International</i> , 2005 , 95 Suppl 2, 8-13	5.6	7
20	Initial experience with laparoscopically assisted percutaneous cryotherapy of renal tumors. <i>Journal of Endourology</i> , 2005 , 19, 480-3	2.7	14
19	A molecular classification of papillary renal cell carcinoma. <i>Cancer Research</i> , 2005 , 65, 5628-37	10.1	185
18	Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3316-22	2.2	278
17	Using protein expressions to predict survival in clear cell renal carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5464-71	12.9	188
16	The role of lymphadenectomy in renal cell carcinoma. <i>Current Urology Reports</i> , 2004 , 5, 25-9	2.9	2
15	Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. <i>Journal of Urology</i> , 2004 , 171, 588-91	2.5	173
14	Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. <i>Journal of Urology</i> , 2004 , 171, 2461-6	2.5	156
13	Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. <i>Journal of Urology</i> , 2004 , 172, 867-70	2.5	44

12	The PAKY, HERMES, AESOP, ZEUS, and da Vinci robotic systems. <i>Urologic Clinics of North America</i> , 2004 , 31, 659-69	2.9	21
11	Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. <i>Journal of Urology</i> , 2004 , 171, 2181-5, quiz 2435	2.5	432
10	Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. <i>Journal of Urology</i> , 2004 , 171, 1810-3	2.5	52
9	Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. <i>Urology</i> , 2004 , 63, 841-6; discussion 846-7	1.6	37
8	Cystic renal cell carcinoma: biology and clinical behavior. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004 , 22, 410-4	2.8	60
7	1774: Nephron-Sparing Surgery as the New Gold Standard for T1 (7 CM) Renal Cell Carcinoma: Results of a Contemporary Ucla Series. <i>Journal of Urology</i> , 2004 , 171, 469-469	2.5	8
6	Immune gene therapy for kidney cancer: the search for a magic trigger. <i>Molecular Therapy</i> , 2003 , 7, 153-41.7	1.7	5
5	Monoclonal antibody (MAB) in patients with advanced cancer. <i>Current Urology Reports</i> , 2003 , 4, 11-2	2.9	1
4	Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. <i>Journal of Urology</i> , 2003 , 170, 2221-4	2.5	60
3	Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. <i>Urologic Clinics of North America</i> , 2003 , 30, 843-52	2.9	554
2	Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. <i>Journal of Urology</i> , 2003 , 170, 1126-30	2.5	181
1	Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. <i>Journal of Urology</i> , 2003 , 170, 1742-6	2.5	139